View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

   reports
Adam Karlsson ... (+3)
  • Adam Karlsson
  • Rickard Anderkrans
  • Viktor Sundberg
VAC.OL VACCIBODY

Vaccibody - Terminating coverage

ABGSC ceases coverage of Vaccibody Transferring coverage to institutional research Last published estimates are shown in this report

11/05/20 November 5, 2020 9 EN
Adam Karlsson ... (+3)
  • Adam Karlsson
  • Rickard Anderkrans
  • Viktor Sundberg
VAC.OL VACCIBODY

Vaccibody - Joining forces with Genentech/Roche

Historical deal for Vaccibody and Norwegian biotech Enables the expansion into a true platform company New scenarios indicate value of NOK 33-75/share

10/01/20 October 1, 2020 12 EN
Rickard Anderkrans ... (+2)
  • Rickard Anderkrans
  • Viktor Sundberg
VAC.OL VACCIBODY

Vaccibody - Q2’20 report

Solid delivery on its timeline Financial review Still more triggers to come in 2020

08/27/20 August 27, 2020 5 EN
Rickard Anderkrans ... (+2)
  • Rickard Anderkrans
  • Viktor Sundberg
VAC.OL VACCIBODY

Vaccibody - VB N-01: Delivering on its timeline

Finalization of patient enrolment ahead of our timeline More data on VB10.NEO the highlight during 2020 Next milestones ahead

08/21/20 August 21, 2020 5 EN
Rickard Anderkrans ... (+2)
  • Rickard Anderkrans
  • Viktor Sundberg
VAC.OL VACCIBODY

Vaccibody - First patient dosed in Nektar combo

First patient dosed, data expected in Q1’21 (ABGSCe) Supportive preclinical data and interim read-out (SCCHN) Vaccibody delivers on its timeline

08/12/20 August 12, 2020 6 EN
Rickard Anderkrans ... (+2)
  • Rickard Anderkrans
  • Viktor Sundberg
VAC.OL VACCIBODY

Vaccibody - Expanding its potential

Encouraging clinical progress for VB10.NEO & VB10.16 Expanding the platform in infectious diseases Scenarios indicate rNPV range of NOK 16-56/share

08/10/20 August 10, 2020 32 EN
Rickard Anderkrans ... (+2)
  • Rickard Anderkrans
  • Viktor Sundberg
VAC.OL VACCIBODY

Vaccibody - Doses first patient in Phase 2 VB10.16 trial

First VB10.16 dose administered in the VB C-02 trial Encouraging Phase 1/2a results supports study rationale Targeting up to 50 patients, completion in H1’22e

07/02/20 July 2, 2020 5 EN
Øystein Elton Lodgaard ... (+3)
  • Øystein Elton Lodgaard
  • Rickard Anderkrans
  • Viktor Sundberg
VAC.OL VACCIBODY

Vaccibody - COVID-19 impact and business update

COVID-19 impact More details on the strategy for its new business area Milestones in 2020

04/16/20 April 16, 2020 6 EN
Øystein Elton Lodgaard ... (+3)
  • Øystein Elton Lodgaard
  • Rickard Anderkrans
  • Viktor Sundberg
VAC.OL VACCIBODY

Vaccibody - Infectious diseases – next step for Vaccibody

A top level recruitment to spearhead a new business area Adding an additional disease area to its platform Transfer of coverage

04/01/20 April 1, 2020 5 EN
Øystein Elton Lodgaard ... (+3)
  • Øystein Elton Lodgaard
  • Rickard Anderkrans
  • Viktor Sundberg
VAC.OL VACCIBODY

Vaccibody - Takeaways from CMD

Clinical responses observed in 50% of all patients Neoepitope selection – a key factor Study expansion

11/14/19 November 14, 2019 5 EN
Jannick Lindegaard Denholt ... (+2)
  • Jannick Lindegaard Denholt
  • Øystein Elton Lodgaard
PREMIUM
VAC.OL VACCIBODY

Vaccibody - Q2: A stepping stone

Neoantigen vaccine suited for personalised treatment At forefront of individualised cancer neoantigen vaccines Huge upside potential, but also some downside protection

08/19/19 August 19, 2019 40 EN
New interest

Save your current filters as a new Interest

Please enter a name for this interest
Save

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search
Save

ResearchPool Subscriptions

Get the most out of your insights

Get in touch